Search Results
Your search for ,WHo matches 20421 pages
Showing 6051 - 6100Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinomas (SCC) originating in the oropharynx, oral cavity, larynx, or hypopharynx are the most common. Today, we recognize different types of head and neck cancers, primarily those that are human...
Study Evaluates Method to Reduce Medication Errors and Side Effects of Newer Oral Anticancer Drugs
In the German AMBORA trial reported in the Journal of Clinical Oncology, Dürr et al found that an intensified clinical pharmacologic/pharmaceutical care initiative reduced medication errors and severe side effects, as well as improved treatment satisfaction, among patients receiving newer oral...
Adjuvant Nivolumab for Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemoradiotherapy: CheckMate 577
As reported in The New England Journal of Medicine by Ronan J. Kelly, MBBCh, MBA, and colleagues, an interim analysis of the phase III CheckMate 577 trial has shown a significant improvement in disease-free survival with adjuvant nivolumab vs placebo in patients with resected esophageal or...
Cancer Aneuploidy May Predict Response to Immunotherapy in Patients With NSCLC
Lower levels of cancer aneuploidy were associated with more favorable outcomes after immune checkpoint inhibition in patients with non–small cell lung cancer (NSCLC), according to data presented by Alessi et al at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021...
Tumor Mutational Burden as Predictor of Immune Response: Variance Between Female and Male Patients With Melanoma
Tumor mutational burden (TMB) was an accurate predictor of response to treatment with immune checkpoint inhibitors for female patients with melanoma, but not for male patients, according to results of a study presented by Sinha et al during the virtual American Association for Cancer Research...
Expert Point of View: Jacqueline S. Garcia, MD
Jacqueline S. Garcia, MD, of Dana-Farber Cancer Institute, who was not involved in this study, agreed that “novel therapies for relapsed/refractory AML that are biomarker-directed are a dire unmet need and may help patients avoid ineffective therapies and unnecessary toxicity.” She noted that 36%...
RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American Society of...
FDA Grants Accelerated Approval to Sacituzumab Govitecan-hziy for Advanced Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sacituzumab govitecan-hziy (Trodelvy) for patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor....
Pediatric Patients With High-Grade Gliomas: Treatment With Oncolytic HSV-1 G207 Immunovirotherapy
In a phase I trial reported at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract CT018) and simultaneously published in The New England Journal of Medicine, Friedman et al found that oncolytic virotherapy with genetically engineered herpes simplex virus-1...
Anesthesiologist Volume and Adverse Short-Term Outcomes After Complex Surgery for Gastrointestinal Cancer
In a Canadian study reported in JAMA Surgery, Hallet et al found that higher anesthesiologist volume was associated with reduced risk of short-term adverse postoperative outcomes in patients undergoing complex surgery for gastrointestinal cancer. Study Details The population-based cohort study...
Long-Term Follow-up of Children and Young Adults With B-Cell ALL Treated With CD19 CAR T-Cell Therapy
In a long-term follow-up of a National Cancer Institute (NCI) phase I trial reported in the Journal of Clinical Oncology, Nirali N. Shah, MD, and colleagues found that autologous CD19 chimeric antigen receptor (CAR) T-cell therapy followed by allogeneic hematopoietic stem cell transplantation can...
Liquid Biopsy Plus MRI for Predicting Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
Cirmena et al discussed whether using a liquid biopsy test to assess plasma cell-free DNA (cfDNA) integrity could improve the accuracy of magnetic resonance imaging (MRI) for predicting the achievement of complete response among patients with locally advanced breast cancer who had received...
Patients With Ovarian Cancer Face an Increased Risk of Mental Illness
Women diagnosed with ovarian cancer were more than three times more likely than the general public to be diagnosed with anxiety, depression, and adjustment disorder, according to results presented by Hu et al during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021...
Patients of Different Races With Early-Onset Colorectal Cancer Exhibit Distinct Genetic Features
Racial differences in genetic mutations were observed among patients with early-onset colorectal cancer, according to data presented by Andreana N. Holowatyj, PhD, MS, during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract 101). The incidence of early-onset ...
American Cancer Society Names Karen E. Knudsen, MBA, PhD, as Its Next Chief Executive Officer
Karen E. Knudsen, MBA, PhD, will be the next Chief Executive Officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN), starting June 1, 2021. She will take the reins from the retiring Gary Reedy, who has served as both...
News From the AACR Annual Meeting: NSCLC, Lymphoma, and Uveal Melanoma
The 2021 AACR Annual Meeting launched week 1 of a 2-week program on April 10, featuring plenary sessions and major scientific symposia. In this week’s podcast, The ASCO Post speaks with faculty from the meeting who presented clinical research in non–small cell lung cancer, non-Hodgkin lymphoma, and ...
Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response Rate for Patients With Resectable NSCLC
Neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathologic complete response (pCR) rates compared with chemotherapy alone in patients with resectable stage IB to IIIA non–small cell lung cancer (NSCLC), according to results of the randomized, phase III, open-label...
Copanlisib/Rituximab Extends Progression-Free Survival vs Rituximab/Placebo in Indolent Non-Hodgkin Lymphoma
The combination of copanlisib plus rituximab reduced the risk of disease progression or death by 48% compared with placebo plus rituximab in patients with indolent non-Hodgkin lymphoma, according to results of the phase III CHRONOS-3 trial presented by Matthew J. Matasar, MD, at the virtual...
Tebentafusp: First Treatment to Improve Overall Survival in Metastatic Uveal Melanoma
Treatment with tebentafusp, a novel bispecific fusion protein, reduced the risk of death from metastatic uveal melanoma at 14 months by half, compared with available treatments, in a phase III study presented by Piperno-Neumann et al at the virtual American Association for Cancer Research (AACR)...
Belzutifan Shows Activity in Advanced Renal Cell Carcinoma, Both as a Single Agent and in Combination Therapy
Separate studies presented at the 2021 Genitourinary Cancers Symposium provide supportive evidence for belzutifan (formerly MK-6482) as an active treatment for metastatic clear cell renal cell carcinoma (RCC). One study showed single-agent activity for this novel approach in an early-phase trial,...
Unselected Autologous Tumor-Infiltrating Lymphocyte Therapy for Metastatic Cutaneous Melanoma
Treatment with unselected autologous tumor-infiltrating lymphocytes (TILs) showed early clinical efficacy among patients with advanced melanoma, according to results presented by Hawkins et al during week 1 of the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract ...
Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
Bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy was well tolerated and showed signs of clinical efficacy in patients with relapsed/refractory B-cell lymphoma, according to phase I clinical trial data presented by Ghafouri et al during week 1 of the virtual American...
Cancer and COVID-19: Reflections at 1 Year
We who live and work in Seattle recently took note of two milestones: the first death of a patient from COVID-19 reported in the United States in Seattle on February 28, 2020, and recognition of 5,000 deaths from COVID-19 in the state of Washington on March 2, 2021. The juxtaposition of these two...
Knuckles
The swastikas on his knuckles kept stealing my attention. I tried not to stare but every time he gestured to emphasize his words my gaze snapped back there. That awful symbol, multiplied across all 10 digits, refused to be ignored. The blue lines were blurred and misshapen, probably jail tats. I...
Legislation Aims to Increase HPV Vaccine Awareness, Access, and Research
ASCO has endorsed the “PREVENT HPV Cancers Act” (H.R. 1550), which was recently introduced by Representative Kathy Castor (FL-14). In a recent letter to the lawmaker, ASCO thanked Rep. Castor for introducing this important measure to increase research on, awareness of, and access to the vaccine,...
Novel Insights in Myelodysplastic Syndromes: Highlights From 2020 ASH Meeting
To complement The ASCO Post’s comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel clinical trial findings in myelodysplastic syndromes (MDS). For full details of...
Jeff Walker, MBA, Returns to Roswell Park in Newly Created Executive Role
An experienced executive has rejoined the Roswell Park Comprehensive Cancer Center team, announced Roswell Park President and Chief Executive Officer Candace S. Johnson, PhD. Jeff Walker, MBA, has been recruited back to Western New York to fill the new role of Executive Vice President of Operations ...
Andrew Ewald, PhD, Named Director of Johns Hopkins Medicine’s Department of Cell Biology
Cancer researcher Andrew Ewald, PhD, has been appointed Director of the Department of Cell Biology at the Johns Hopkins University School of Medicine. He will take over the position from Peter Devreotes, PhD, who will remain on the faculty at Johns Hopkins. Dr. Ewald joined the medical school...
Johan Vansteenkiste, MD, PhD, and Fiona Blackhall, PhD, FRCP, Honored for Lung Cancer Research by ESMO and IASLC
The European Society for Medical Oncology and the International Association for the Study of Lung Cancer recently presented the Heine H. Hansen Award 2021 to Johan Vansteenkiste, MD, PhD, Professor of Medicine at the Catholic University of Leuven and Head of Clinic in the Respiratory Oncology Unit...
Lung Cancers With Rare EGFR Mutations Being Tackled by Novel Agents
Next-generation inhibitors of epidermal growth factor receptor (EGFR) exon 20 insertion mutations showed promise in patients with advanced non–small cell lung cancer (NSCLC) in early-phase trials presented during the International Association Society for Lung Cancer 2020 World Conference on Lung...
Cardiovascular Concerns With the Use of VEGFR Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGFR) have proved to be effective drugs in the treatment of many solid tumors. However, their clinical benefit may come at the cost of cardiovascular toxicity if clinicians are not vigilant and proactive. During...
Novel Decision-Making Tool for Androgen-Deprivation Therapy for Patients With Prostate Cancer
According to a retrospective study, the combined clinical and cell-cycle risk (CCR) score may be able to accurately predict which patients with intermediate- and high-risk prostate cancer will have little additional benefit from androgen-deprivation therapy added to dose-escalated radiotherapy and...
Ze’ev Ronai, PhD, Named Director of Sanford Burnham Prebys Cancer Center
Sanford Burnham Prebys Medical Discovery Institute has appointed cancer researcher Ze’ev Ronai, PhD, as Director of its National Cancer Institute (NCI)-designated Cancer Center. Established in 1976, the Cancer Center is one of only seven NCI-designated Basic Laboratory Cancer Centers in the...
Fox Chase Welcomes Cihangir Duy, PhD, MS
Fox Chase Cancer Center recently welcomed Cihangir Duy, PhD, MS, who has joined the Cancer Signaling and Epigenetics Program as Assistant Professor. Before coming to Fox Chase, Dr. Duy was Instructor in Cell and Developmental Biology at Weill Cornell Medicine Graduate School of Medical Sciences in...
Expert Point of View: Xin Gao, MD
Xin Gao, MD, a medical oncologist at Mass General Hospital and Instructor at Harvard Medical School, said these were important findings. “Analyses of patient-reported outcomes pertaining to health-related quality-of-life measures from CheckMate 9ER showed significantly improved quality-of-life...
Patient-Reported Outcomes With Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
Results of the CheckMate 9ER phase III trial showed significantly improved patient-reported outcomes in quality of life for first-line treatment with nivolumab plus cabozantinib compared with sunitinib for patients with advanced renal cell carcinoma.1 These findings are in line with the previously...
Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer
In the first report from the pivotal phase III KEYNOTE-775/Study 309 trial, the combination of lenvatinib, a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3 kinases, and pembrolizumab significantly improved multiple outcomes compared with standard single-agent chemotherapy in patients with...
Towering Figure in Cancer Drug Development, José Baselga, MD, PhD, FASCO, Dies at Age 61
José Baselga, MD, PhD, FASCO, a global innovator in novel cancer therapeutics, led research efforts in his native country of Spain and in the United States, most notably as Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK). “My moment of recognition as an oncologist came early,...
Yoga in Oncologic Care: An Evidence-Based Treatment to Improve Outcomes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Increasingly, patients with cancer desire nonpharmacologic strategies for managing their...
I’m Living the Life I Was Destined to Have
At 33, I’m not living the life I had imagined for myself. If cancer hadn’t interrupted my plans, I would be serving in the United States Army Special Forces by now, a profession that was inspired by my father’s career as a military officer and helicopter pilot and one that I had dreamed about since ...
An Oncologist and His Wife Share a Personal Cancer Story
Gastrointestinal oncologist John Marshall, MD, is well known for his candid observations about cancer treatment and research. In 2006, all the scientific intricacies and sociopolitical dramas of oncology coalesced in Dr. Marshall’s life when his 43-year-old wife, Liza, was diagnosed with breast...
Breast Cancer Screening With Clinical Breast Examination in Low- and Middle-Income Countries
Globally, breast cancer surpassed lung cancer as the most common cancer among women, with an estimated 2.3 million cases in 2020.1,2 Approximately 685,000 women will die of breast cancer in 2020 around the world. Approximately 24.5% of all cancers in women are breast cancer, and 15.5% of...
William Tseng, MD, Joins Sarcoma Alliance Board of Directors
The Sarcoma Alliance recently announced the appointment of William Tseng, MD, to the organization’s Board of Directors. A surgical oncologist at Keck Medicine of the University of Southern California (USC), Dr. Tseng specializes in soft-tissue sarcoma. “Our Board of Directors comprises a...
New Jersey Oncology Care Providers Form Astera Cancer Care, Join OneOncology
A group of 37 medical and radiation oncologists—along with a staff of cancer-care providers, led by Bruno S. Fang, MD, and Edward J. Licitra, MD, PhD, who currently constitute the Central Jersey Division of Regional Cancer Care Associates—are forming Astera Cancer Care, an independent and...
Pembrolizumab in First-Line Treatment of Metastatic Clear Cell and Non–Clear Cell Renal Cell Carcinoma
The treatment paradigm for patients with metastatic renal cell carcinoma has undergone a dramatic shift over the past few years, improving outcomes for many patients but leaving many unanswered questions as to how to optimally choose the best treatment for an individual patient. The changes are...
How Exceptional Responders Are Providing Clues to Personalizing Cancer Treatment
The findings from a recent study of patients with cancer who had an exceptional response to chemotherapy are yielding new clues on the molecular changes in patients’ tumors. These findings may explain the genetic alterations contributing to these patients’ dramatic and long-lasting responses to...
Discrepancies in HER2 Assessment for Metastatic Gastric Cancer
In the German VARIANZ study reported in the Journal of Clinical Oncology, Haffner et al found discrepancies between findings in central and local testing of HER2 status in patients with metastatic gastric cancer. In addition, survival outcomes among patients treated with trastuzumab were better...
Cardiovascular Disease in Hematologic Malignancies: Who Is at Risk?
Given the improvements in diagnostic strategies, treatment, and supportive care, long-term survival is now an expected outcome for a large majority of patients with hematologic malignancies. Unfortunately, radiation therapy and anthracyclines, which form the backbone of front-line treatment, have...
FDA Grants Regular Approval to Sacituzumab Govitecan-hziy for Pretreated Patients With Triple-Negative Breast Cancer
On April 7, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan-hziy (Trodelvy) for patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them...
Oral Azacitidine in Lower-Risk Myelodysplastic Syndromes
In a phase III trial reported in the Journal of Clinical Oncology, Guillermo Garcia-Manero, MD, and colleagues found that oral azacitidine significantly improved red blood cell (RBC) transfusion independence vs placebo in patients with lower-risk myelodysplastic syndromes. An increase in early...
